Hep-b approval and Corona vaccine trial updates imminentMore than doubling of the Hep-B vaccine market, Dynavax's primary revenue source, looks very likely:
https://www.prnewswire.com/news-releases/european-chmp-adopts-positive-opinion-for-heplisav-b-dynavaxs-two-dose-adult-hepatitis-b-adjuvanted-vaccine-301190681.html
This, alongside news from the multiple Covid trials Dynavax contributed an adjuvant for, bodes well for a doubling of the stock once again. $5 to $10, as we saw in the summer, looks likely to me within the next quarter, depending on Covid results. This could be especially important in light of reported setbacks my vaccine giant GSK. Door is open build on success from Moderna and Pfizer.